CAR T-cell structure

CARs are typically composed of four regions: (1) an extracellular antigen-binding domain; (2) a hinge or spacer peptide; (3) a transmembrane domain that anchors the CAR to the cell membrane; and (4) one or more intracellular signalling domains that leads to T-cell activation.5-7The extracellular antigen-binding domain is derived from a single-chain variable fragment (scFv) constructed through fusion of the antigen-binding regions of both heavy (VH) and light (VL) chains of a monoclonal antibody.6,8The intracellular signalling domain is most commonly derived from lymphocyte signal-initiating molecules including the CD3 zeta-chain (CD3z) of the T-cell receptor (TCR)/CD3 complex.9Incorporation of additional co-stimulatory signalling proteins, such as the CD28 family or the tumour necrosis factor receptor (TNFR) family of genes, can augment the ability of CARs to stimulate cytokine secretion, potentiate T-cell persistence and enhance anti-tumour efficacy.7,10

In chimeric antigen receptor (CAR) T-cell immunotherapy, autologous effector T-cells are harvested from the peripheral blood of patients with cancer through leukapheresis and genetically engineered ex vivousing a lentiviral or gammaretroviral vector to express synthetic proteins known as CAR receptors.1-4These receptors are directed against pre-determined cell-surface antigens expressed on tumor cells.1-4Lymphodepleting chemotherapy is given to the patient and then the re-programmed CAR T-cells are infused back into the patient, where they induce a selective immune response against tumor cells expressing the corresponding antigen.3,4

Approved CAR T-cell therapies

CAR T-cell immunotherapy has shown promising results in clinical trials with high rates of durable responses achieved in patients with pre-treated and chemotherapy-resistant chronic and acute B-cell precursor lymphoblastic leukaemia (B-ALL) and B-cell lymphoma.11-15Consequently, in August 2017, the FDA approved tisagenlecleucel, a CD19-directed CAR T-cell therapy for the treatment of relapsed or refractory B-cell ALL in patients under 25 years old.16Shortly thereafter, in October 2017, axicabtagene ciloleucel, another CD-19-directed T-cell therapy was approved for use in adult patients with relapsed or refractory large B-cell lymphoma.17More recently, in May 2018, tisagenlecleucel gained additional approval for the treatment of relapsed or refractory large B-cell lymphoma in adults.18

Key target of CAR T-cell therapy in multiple myeloma  

Currently, CAR T-cell therapy is being investigated for the treatment of relapsed or refractory multiple myeloma (MM).14,19-22The principal target of CAR T-cell therapies for multiple myeloma is the B-cell maturation antigen (BCMA).22-24This is a transmembrane glycoprotein expressed exclusively by B-lineage-derived cells, particularly in the interfollicular region of the germinal centers, and on plasmablasts and differentiated plasma cells (PCs).24-27BCMA is selectively induced during PC differentiation, supporting humoral immunity by mediating survival of normal bone marrow PCs and plasmoblasts.23-25,28As BCMA expression is virtually absent on naïve and most memory B-cells, it is not critical for overall B-cell homeostasis but is required for optimal survival of long-lived PCs.26-30In patients with MM, BCMA is widely expressed on malignant PCs at significantly higher levels.22-24Indeed, BCMA expression increases as MM progresses, from normal to monoclonal gammopathy of undetermined significance to smouldering to active MM.22Due to the lineage-restricted expression profile of BCMA and its survival function in plasma cells, it is a potentially viable target for CAR T-cell therapy in patients with MM.22-25Given the poor outcome of patients with relapsed or refractory multiple myeloma, there is a high unmet need for effective treatments. It is hoped that novel treatment options such as CAR T-cell immunotherapy may offer hope for heavily pre-treated patients. 

Medical writing was provided by Atif Riaz, PhD of Prime Global, Knutsford, UK.

Prime Global – Where people come first, science and creativity fuse and truly brilliant communications flow. You can visit them at


1.         Jin C, Fotaki G, Ramachandran M, et al. Safe engineering of CAR T cells for adoptive cell therapy of cancer using long-term episomal gene transfer. EMBO Mol Med. 2016;8:702-711.

2.         Levine BL, Miskin J, Wonnacott K, Keir C. Global Manufacturing of CAR T Cell Therapy. Mol Ther Methods Clin Dev. 2017;4:92-101.

3.         Buechner J, Kersten MJ, Fuchs M, Salmon F, Jäger U. Chimeric Antigen Receptor-T Cell Therapy. HemaSphere. 2018;2:e18.

4.         Hay KA, Turtle CJ. Chimeric Antigen Receptor (CAR) T Cells: Lessons Learned from Targeting of CD19 in B-Cell Malignancies. Drugs. 2017;77:237-245.

5.         Ramos CA, Dotti G. Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy. Expert Opin Biol Ther. 2011;11:855-873.

6.         Gacerez AT, Arellano B, Sentman CL. How Chimeric Antigen Receptor Design Affects Adoptive T Cell Therapy. J Cell Physiol. 2016;231:2590-2598.

7.         Guedan S, Calderon H, Posey AD, Jr., Maus MV. Engineering and Design of Chimeric Antigen Receptors. Mol Ther Methods Clin Dev. 2019;12:145-156.

8.         Dotti G, Gottschalk S, Savoldo B, Brenner MK. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev. 2014;257:107-126.

9.         Dai H, Wang Y, Lu X, Han W. Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy. J Natl Cancer Inst. 2016;108.

10.      Milone MC, Fish JD, Carpenito C, et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther. 2009;17:1453-1464.

11.      Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365:725-733.

12.      Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507-1517.

13.      Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018;378:439-448.

14.      Kriegsmann K, Kriegsmann M, Cremer M, et al. Cell-based immunotherapy approaches for multiple myeloma. Br J Cancer. 2019;120:38-44.

15.      Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2019;380:45-56.

16.      U.S. Food and Drug Administration. FDA approves tisagenlecleucel for B-cell ALL and tocilizumab for cytokine release syndrome. Accessed 20 February.

17.      U.S. Food and Drug Administration. FDA approves axicabtagene ciloleucel for large B-cell lymphoma. Accessed 20 February.

18.      U.S. Food and Drug Administration. FDA approves tisagenlecleucel for adults with relapsed or refractory large B-cell lymphoma. Accessed 20 February.

19.      Ali SA, Shi V, Maric I, et al. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood. 2016;128:1688-1700.

20.      Fan F, Zhao W, Liu J, et al. Durable remissions with BCMA-specific chimeric antigen receptor (CAR)-modified T cells in patients with refractory/relapsed multiple myeloma. J Clin Oncol. 2017;35:LBA3001.

21.      Raje NS, Berdeja JG, Lin Y, et al. bb2121 anti-BCMA CAR T-cell therapy in patients with relapsed/refractory multiple myeloma: Updated results from a multicenter phase I study. J Clin Oncol. 2018;36:8007.

22.      Tai YT, Anderson KC. Targeting B-cell maturation antigen in multiple myeloma. Immunotherapy. 2015;7:1187-1199.

23.      Trudel S, Lendvai N, Popat R, et al. Targeting B-cell maturation antigen with GSK2857916 antibody–drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. Lancet Oncol. 2018;19:1641-1653.

24.      Bu DX, Singh R, Choi EE, et al. Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma. Oncotarget. 2018;9:25764-25780.

25.      Carpenter RO, Evbuomwan MO, Pittaluga S, et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res. 2013;19:2048-2060.

26.      Ryan MC, Hering M, Peckham D, et al. Antibody targeting of B-cell maturation antigen on malignant plasma cells. Mol Cancer Ther. 2007;6:3009-3018.

27.      Chiu A, Xu W, He B, et al. Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL. Blood. 2007;109:729-739.

28.      Bossen C, Schneider P. BAFF, APRIL and their receptors: structure, function and signaling. Semin Immunol. 2006;18:263-275.

29.      O’Connor BP, Raman VS, Erickson LD, et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med. 2004;199:91-98.

30.      Avery DT, Kalled SL, Ellyard JI, et al. BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J Clin Invest. 2003;112:286-297.

Featured What Are Chimeric Antigen Receptor (CAR) T-cells and What is Their Potential Target Site in Multiple Myeloma?